Increased ErbB3 and EGFR activity mediate lapatinib resistance in prostate cancer

被引：0
|
作者：
Jathal, Maitreyee K. [1 ]
Steele, Thomas M. [2 ]
Mooso, Benjamin A. [2 ]
D'Abronzo, Leandro S. [1 ]
Siddiqui, Salma [2 ]
Drake, Christiana [1 ]
Ghosh, Paramita M. [1 ]
机构：
[1] Univ Calif Davis, Davis, CA USA
[2] VA Med Ctr, Sacramento, CA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3335
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance
    Chen, Yutao
    Lu, Anni
    Hu, Zhangli
    Li, Jinyao
    Lu, Jun
    CANCER LETTERS, 2024, 599
  • [22] Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    Frogne, Thomas
    Benjaminsen, Rikke V.
    Sonne-Hansen, Katrine
    Sorensen, Boe S.
    Nexo, Ebba
    Laenkholm, Anne-Vibeke
    Rasmussen, Louise M.
    Riese, David J., II
    de Cremoux, Patricia
    Stenvang, Jan
    Lykkesfeldt, Anne E.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (02) : 263 - 275
  • [23] Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    Thomas Frogne
    Rikke V. Benjaminsen
    Katrine Sonne-Hansen
    Boe S. Sorensen
    Ebba Nexo
    Anne-Vibeke Laenkholm
    Louise M. Rasmussen
    David J. Riese
    Patricia de Cremoux
    Jan Stenvang
    Anne E. Lykkesfeldt
    Breast Cancer Research and Treatment, 2009, 114
  • [24] ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib
    Frolov, Andrey
    Schuller, Kyle
    Tzeng, Ching-Wei D.
    Cannon, Emily E.
    Ku, Brandon C.
    Howard, J. Harrison
    Vickers, Selwyn M.
    Heslin, Martin J.
    Buchsbaum, Donald J.
    Arnoletti, J. Pablo
    CANCER BIOLOGY & THERAPY, 2007, 6 (04) : 548 - 554
  • [25] Targeting on ErbB3 for cancer therapy
    Liu, Xifu
    Li, Xingyan
    Zhou, Mingdong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 8 - 8
  • [26] ErbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells
    Wang, Shuiliang
    Gao, Lizhi
    Huang, Xiaoping
    Liu, Bolin
    CANCER RESEARCH, 2009, 69
  • [27] Role of ErbB3 in tumorigenesis and drug resistance in ErbB2-driven breast cancer
    Lyu, Hui
    Huang, Jingcao
    Edgerton, Susan M.
    Thor, Ann D.
    Liu, Bolin
    CLINICAL CANCER RESEARCH, 2015, 21
  • [28] Differential effects of erbB3 and IGF-1R signaling on lapatinib resistance acquired by the erbB2-overexpressing breast cancer cells refractory to trastuzumab
    Lyu, Hui
    Huang, Jingcao
    Lee, Youngseok
    Liu, Bolin
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [29] The regulation of nuclear ErbB3 by the androgen receptor in prostate cancer cells.
    Jathal, M. K.
    Steele, T. M.
    Siddiqui, S.
    Ghosh, P. M.
    MOLECULAR BIOLOGY OF THE CELL, 2016, 27
  • [30] Nuclear localization of ERBB3: A potential diagnostic/prognostic marker of prostate cancer
    Koumakpayi, IH
    Diallo, JS
    Le Page, C
    Lessard, L
    Gleave, ME
    Mes-Masson, AM
    Saad, F
    JOURNAL OF UROLOGY, 2005, 173 (04): : 105 - 106
12345